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Background: Whether familial papillary thyroid cancer (FPTC) is more aggressive than sporadic counterpart remains
elusive, and the optimal clinical approach for FPTC is yet to be established. In this study, we investigated familial
occurrence of PTC in China and reviewed our experience of its surgical treatment.
Methods: The clinical records of 248 consecutive patients with an established diagnosis of PTC who were admitted
to Nanfang Hospital for thyroidectomy between January 2011 and June 2013 were analyzed in this study. Patients
included 66 males and 182 females, aged 11 to 76 years.
Results: Twenty-two patients (8.9%) with a positive family history were confirmed. Patients with FPTC had a
predilection for female subjects and tended to be younger than other patients, but the difference was not
significant (P = 0.0514 and P = 0.168). They were more likely to present large tumors (P = 0.0024), multifocality
(familial vs. sporadic: 54.50% vs. 26.50%; P < 0.006), local invasion (81.8% vs. 23.9%; P < 0.001), and malignant lymph
nodes (63.6% vs. 33.6%; P = 0.005). Univariate and multivariate analyses identified that a positive family history was
an independent risk factor for local invasion (OR: 5.683; 95% CI: 2.056 to 15.707; P = 0.001), malignant lymph nodes
(OR: 3.005; 95% CI: 1.046 to 8.630; P = 0.041) in FPTC patients. Kaplan-Meier survival curves revealed that an aggressive
surgical strategy was associated with a better relapse-free survival than conventional one (P = 0.032).
Conclusions: FPTC is more likely to possess aggressive features than sporadic counterparts. Thus, screening of at-risk
families is essential to aid in earlier recognition. An aggressive surgical strategy appeared to be the more effective
therapy. However, sufficient detailed interrogation and long-term follow-up of the patients and their family are
necessary for providing individualized recommendations for clinical management.
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considerationsBackground
Thyroid cancer is the tenth most common cancer in
China, accounting for approximately 2.29% of all cancers
according to the Chinese Cancer Registry Annual Report
2012 [1]. Over 95% of all thyroid cancers are non-
medullary thyroid cancers (NMTCs) that arise from thy-
roid follicular cells, which consist of four histological
types: papillary (85%), follicular (11%), Hurthle cell (3%),
and anaplastic (1%) [2]. Little evidence has been known
about the epidemiology of rare histological types. The* Correspondence: wonder0618.dw@gmail.com; gzliguoxin@163.com
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has been continually increasing in the past decades in
the countries from East Asia and the West. Though
most PTC arises sporadically, it is estimated that a famil-
ial origin is present in 3.5% to 6.2% of cases, and the rate
in women is twice that in men [3]. There are some
established risk factors, such as ionizing radiation, iodine
deficiency, and goiter. In addition, a number of studies
have provided strong evidence for a genetic basis of PTC
ever since the first description of familial papillary thy-
roid cancer in 1955 by Robinson and Orr [4].
Familial papillary thyroid cancer (FPTC) is now de-
fined by a diagnosis of at least two first-degree relatives
with PTC without another familial syndrome. This ex-
cludes PTC of distinct types that can be a component in
some Mendelian-inherited cancer syndromes, such ass is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of patients included in
this study




Age (years, mean ± SD) 40.40 ± 13.35
<45 158
≥45 94
Histological types: papillary 248




Median number of tLNs (range) 9(0 to 119)




SD: standard deviation, tLN: total resected lymph nodes, mLN: metastatic
lymph nodes, AJCC: American Joint Committee on Cancer.
Lei et al. World Journal of Surgical Oncology  (2015) 13:115 Page 2 of 7familial adenomatous polyposis, Cowden’s syndrome,
Werner syndrome, Carney complex, and Peutz-Jeghers
syndrome. Cases of PTC are documented to be associ-
ated with a younger age at presentation; they are more
aggressive than sporadic PTC and associated with higher
recurrence [2]. However, registry-based data are rare.
There is no general agreement on the best surgical
management strategy for FPTC. Therefore, the aim of
the study is to investigate the occurrence of FPTC in a
single center in China and identify factors in our data-
base that were taken into consideration for surgical
treatment of FPTC. The results may contribute to estab-
lishment of an optimal clinical approach for patients
with this type of cancer.
Methods
Patients
A total of 248 consecutive patients admitted to Nanfang
Hospital with an established diagnosis of PTC to
undergo thyroidectomy between January 2011 and June
2013 were included in this study. All study patients were
questioned regarding the presence or absence of simi-
larly affected family members. A family history was
considered positive when patients had at least two first-
degree relatives with PTC. Family history and medical
information, including demographics, radiation expos-
ure, additional syndromes, surgical information, and
pathological diagnosis, were recorded in the database.
Stage of thyroid cancer was described according to the
2010 tumor node metastasis (TNM) classification of
malignant tumors by the American Joint Committee on
Cancer (AJCC). All patients underwent total thyroidec-
tomy and modified neck dissection as the American
Thyroid Association recommended except 13 FPTC
cases after January 2012. These 13 patients were cate-
gorized into the aggressive surgery group (AG) and the
remaining FPTC patients into the conventional surgery
group (CG). An aggressive surgical strategy was used in
AG; briefly, we performed a prophylactic central neck
dissection in any FPTC patient with a primary tumor
of >1 cm in size or smaller tumor but exhibiting local
invasion including minimal extrathyroidal extension or
invasion to adjacent organs and a lateral neck dissec-
tion should be considered if enlarged and suspicious
nodes were detected in the cervicolateral compartment
in advanced carcinomas. Complete follow-up, ranging
from 16 to 36 months, was available for all FPTC
patients.
Ethics statement
All patients provided written informed consents for the
storage and use of their data. This study was approved
by the Ethics Committee of Nanfang Hospital, Southern
Medical University, China.Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical software package (SPSS® version 16.0) (SPSS Inc.;
Chicago, IL, USA). Where appropriate, the Mann–Whitney
U-test, two-tailed t-test, and Fisher’s exact test was used for
comparisons between two independent groups. A logistic
regression model was used to assess odds ratios (ORs) and
identify factors that familial risks independently predict. A dif-
ference between two mean values was considered significant
when P < 0.05.
Results
A total of 248 consecutive patients were entered in the
study, including 66 males and 182 females of aged 11 to
76 years (mean age: 40.40 years) (Table 1). Among them,
nodular goiter occurred in 106 cases, thyroid adenoma
in 86, and Hashimoto’s thyroiditis in 38. Median number
of total removed lymph nodes was 9. And the numbers
of patients with stage I (<45), II (<45), I (≥45), II (≥45),
III (≥45), and IV (≥45) thyroid cancer were 146, 8, 28,
10, 26, and 30, respectively, according to AJCC classifi-
cation. The familial relationship between the affected
family members was illustrated in Table 2.
Of the 248 study patients, 22 were confirmed with a
positive family history. Comparing clinicopathologic
characteristics between familial and sporadic PTC pa-
tients in the present study, we found that patients with
any positive family history were more likely to exhibit
tumors of larger size (36.4% vs. 12.4%; P = 0.0024), mul-
tifocality (54.50% vs. 26.50%; P = 0.006), local invasion




(years, mean ± SD)
Tumor size







First generation (n =
12)
0/12 35.17 ± 12.90 2.10 ± 1.35 8(66.7%) 0(0.00%) 12(100.0%) 10(83.3%)
Second generation (n
= 10)
2/8 38.40 ± 14.93 2.40 ± 1.80 4(40.0%) 4(40.0%) 6(60.0%) 4(40.0%)
P 0.195 0.592 0.670 0.391 0.029 0.029 0.074
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nodes (63.6% vs. 33.33%; P = 0.005) (Table 3). However,
familial occurrence of PTC was not significantly associ-
ated with age at diagnosis, gender, median number of
total resected lymph nodes, median number of meta-
static lymph nodes, combination with benign thyroid
diseases, or AJCC stage.
To further validate the effect of familial occurrence
of PTC on tumor aggressiveness, univariate and
multivariate analyses identified that a positive family
history was an independent risk factor for localTable 3 Clinicopathologic characteristics of familial and spora












Malignant lymph nodes 14(63.6%)
Number of tLNs: median (range) 7(0 to 37)
Number of mLNs: median (range) 1(0 to 19)






I + II 6(27.3%)
III + IV 4(18.2%)
Relapse 3(13.6%)
SD: standard deviation, tLN: total resected lymph nodes, mLN: metastatic lymph no
minimal extrathyroidal extension and invasion to esophagus, larynx, recurrent laryninvasion (OR: 5.683; 95% CI: 2.056 to 15.707; P =
0.001) (Table 4) and malignant lymph nodes (OR:
3.005; 95% CI: 1.046 to 8.630; P = 0.041) (Table 5) in
FPTC patients but not for tumor size (Table 6) and
multifocality (Table 7).
Because of the high rate of recurrence and lymphatic
metastases seen in FPTC patients in the early period of
this study and the association between reported appre-
ciable death rate and recurrence, a more aggressive sur-
gical strategy has been applied to treat FPTC since
January 2012. Kaplan-Meier survival curves revealed thatdic PTC patients












9(0 to 119) 0.660









des, AJCC: American Joint Committee on Cancer. aLocal invasion including
geal nerve, and subcutaneous soft tissues.
Table 4 Univariate and multivariate analyses of risk factors predicting local invasion in FPTC patients
Univariatea Multivariateb
OR 95% CI P OR 95% CI P
Group 8.494 3.166, 22.786 <0.001 5.683 2.056, 15.707 0.001
Gender 2.105 1.046, 4.234 0.037 2.010 0.957, 4.223 0.065
Age 1.857 1.058, 3.259 0.031 2.306 1.218, 4.365 0.010
Tumor size 1.975 0.935, 4.172 0.075 1.425 0.617, 3.290 0.407
Multifocality 1.024 0.555, 1.890 0.940
Rapid proliferation 1.991 0.786, 5.042 0.146
Metastatic lymph nodes 2.431 1.379, 4.288 0.002 2.542 1.345, 4.804 0.004
Group: familial vs. sporadic, Gender: female vs. male, Age (years): ≥45 vs. <45, Tumor size (cm): >4 vs. ≤4, Multifocality: yes vs. no, Rapid proliferation: yes vs. no,
Metastatic lymph nodes: yes vs. no; OR: odds ratio, CI: confidence interval. aHazard ratios in univariate models; bHazard ratios in multivariable models.
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ter relapse-free survival than conventional one (P =
0.032) (Figure 1).
Discussion
Although frequently reported, whether FPTC patients
shows a more aggressive behavior than their sporadic
counterparts and whether FPTC requires more extended
surgical procedures, such as total thyroidectomy and
prophylactic neck dissection, remain inconclusive. Fur-
thermore, there is no general recommendation to what
extent non-affected family members should be screened
for occult thyroid malignancy.
The prevalence of FPTC is difficult to establish due to
the low incidence. We observed a familial incidence of
8.9% in 248 PTC cases enrolled in our study, and the
age of FPTC patients was younger; whereas no signifi-
cant association with age at diagnosis was noted [5]. In
addition, the female:male ratio of FPTC patients was 5:1
in our study, higher than the ratio of 2:1 and 3:1 previ-
ously reported [6], whereas consistent with the findings
from Orsenigo’s study [7]. It probably results from the
sampling pool in this study.
FPTC is reported to behave more aggressively than
sporadic pattern and correlate with early age of onset, in-
creased incidence of benign thyroid nodules, multifocality,Table 5 Univariate and multivariate analyses of risk factors p
Univariatea
OR 95% CI
Group 3.454 1.388, 8.593
Gender 0.996 0.554, 1.788
Age 0.457 0.260, 0.803
Tumor size 1.271 0.608, 2.659
Multifocality 0.885 0.496, 1.581
Rapid proliferation 0.340 0.162, 0.713
Local invasion 2.431 1.379, 4.288
Group: familial vs. sporadic, Gender: female vs. male, Age (years): ≥45 vs. <45, (cm):
invasion: yes vs. no; OR: odds ratio, CI: confidence interval. aHazard ratios in univarianodal involvement, and recurrence [8-10]. Mazeh et al.
[10] found that compared with non-FPTC counterparts,
patients with FPTC had similar tumor size but were sig-
nificantly younger and more likely to present with multi-
centricity, malignant lymph nodes, and local invasion into
surrounding tissues and higher recurrence rate. In a Japa-
nese study, Ito [11] also regarded the occurrence of multi-
centricity and dramatically increased recurrence of thyroid
cancer to be significant in their FPTC patients. However,
lymph node metastasis, local invasion to surrounding
tissues, and disease-free survival rate did not significantly
differ between patients with sporadic PTC and FPTC [12].
Several characteristics in FPTC patients are associated
with a poor prognosis. The primary feature is the aggres-
siveness of PTC. FPTC is associated with a higher risk of
invasiveness and lymph node invasion. The recurrence
of PTC is associated with a worse prognosis, even in a
low-risk patient. The recurrence rate of FPTC is higher
than that of sporadic PTC. The mortality of patients
with recurrent PTC is up to 33.33% [2,9].
Contradicting results have been obtained in terms of
familial and sporadic PTC. McDonald [5] statistically
compared the clinical and pathologic data between
FPTC and sporadic PTC patients using chi-square test
and demonstrated no statistically significant trends in
surgical pathological parameters, age at presentation,redicting malignant lymph nodes in FPTC patients
Multivariateb
P OR 95% CI P
0.008 3.005 1.046, 8.630 0.041
0.988
0.006 0.353 0.190,0.655 0.001
0.524
0.681
0.004 0.262 0.119, 0.575 0.001
0.002 2.833 1.486, 5.399 0.002
>4 vs. ≤4, Multifocality: yes vs. no, Rapid proliferation: yes vs. no, Local
te models; bHazard ratios in multivariable models.
Table 6 Univariate and multivariate analyses of risk factors predicting larger tumor size in FPTC patients
Univariatea Multivariateb
OR 95% CI P OR 95% CI P
Group 2.652 0.958, 7.341 0.061 2.122 0.726, 6.204 0.169
Gender 1.208 0.518, 2.821 0.662
Age 2.043 0.958, 4.236 0.055 1.927 0.920, 4.036 0.082
Multifocality 1.467 0.683, 3.154 0.326
Rapid proliferation 1.223 0.402, 3.719 0.723
Local invasion 1.975 0.935, 4.172 0.075 1.564 0.707, 3.460 0.270
Metastatic lymph nodes 1.271 0.608, 2.659 0.524
Group: familial vs. sporadic, Gender: female vs. male, Age (years): ≥45 vs. <45, Multifocality: yes vs. no, Rapid proliferation: yes vs. no, Local invasion: yes vs. no,
Metastatic lymph nodes: yes vs. no; OR: odds ratio, CI: confidence interval. aHazard ratios in univariate models; bHazard ratios in multivariable models.
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with Mazeh et al. [10], significant trends toward higher
rates of repeated surgery and/or requiring additional
radioactive iodine therapy, distant metastases, and deaths
were seen in the familial PTC group. These aggressive
features were the most apparent in certain families with
three or more affected members [5].
Our findings, in agreement with several reports [2,8,9],
indicated that FPTC is more aggressive than sporadic
PTC, as determined by larger tumor size, increased local
invasion, and malignant lymph node involvement. The
presence of a positive family history is a significant risk
factor of local invasion and lymph node metastases, to
some extent, namely aggressiveness.
It is believed to have a genetic predisposition [13].
Linkage studies have identified the loci within specific
families, including MNG1, TCO1, fPTC/PRN, and so on,
whereas none of these candidates appears to account for
a significant number of cases [14]. Triponez [15] demon-
strated that patients who were diagnosed after an identi-
fied familial link has tended to yield better outcomes,
highlighting the importance of early diagnosis and treat-
ment for optimal outcomes. Until reliable genetic testing
becomes available, obtaining a detailed family history is
of great importance for recognition of any familial link
to FPTC. Recently, Khara et al. reported a 3-year-oldTable 7 Univariate and multivariate analyses of risk factors p
Univariatea
OR 95% CI
Group 2.306 0.947, 5.612
Gender 1.318 0.691, 2.517
Age 1.576 0.898, 2.765
Tumor size 1.467 0.683, 3.154
Rapid proliferation 1.326 0.569, 3.088
Local invasion 1.024 0.555, 1.890
Metastatic lymph nodes 0.885 0.496, 1.581
Group: familial vs. sporadic, Gender: female vs. male, Age (years): ≥45 vs. <45, Tumo
Metastatic lymph nodes: yes vs. no; OR: odds ratio, CI: confidence interval. aHazardboy with familial PTC [16]. Since the patients in the
second generation are frequently younger than the first
generation counterparts, preoperative screening should
be conducted at the age of 18 years according to expert
consensus. Therefore, we suggest that all patients diag-
nosed with PTC should undergo a comprehensive his-
tory to identify potential familial forms of PTC.
To date, no clinical trials have been performed to
establish a primary management strategy for FPTC.
Although it remains controversial, many experts rec-
ommend the application of prophylactic thyroidec-
tomy in patients at risk of FPTC [2,17]. Whether
thyroidectomy should be performed mainly relies
upon the information gained from a careful screen-
ing process of at-risk individuals and examining the
course of disease within a family. Based on our ex-
perience, even lesions as small as ≤1 cm in size in
FPTC patients can be associated with multifocality,
invasion, and lymph node metastasis. We recom-
mend that all patients with FPTC confirmed by bi-
opsy should undergo total thyroidectomy regardless
of tumor size. Our routine surgical procedure is first
to excise the affected side, followed by excision of
the contralateral side. Because of the high rate of
nodal involvement in patients with FPTC, we recommend
performing prophylactic central neck dissection in anyredicting multifocality in FPTC patients
Multivariateb
P OR 95% CI P







r size (cm): >4 vs. ≤4, Rapid proliferation: yes vs. no, Local invasion: yes vs. no,






Figure 1 Kaplan-Meier survival curves in FPTC patients
grouped according to operation strategy. A better relapse-free
survival was observed in FPTC patients in AG than CG (P = 0.032).
AG: aggressive surgery group, CG: conventional surgery group.
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smaller tumor but with local invasion to surrounding
tissues. In advanced carcinomas, if preoperative
ultrasound shows enlarged and suspicious nodes in
the cervicolateral compartment, a lateral neck dis-
section should be considered. The high recurrence
rate seen in these patients and the reported appre-
ciable death rate associated with recurrence lead us
to believe that almost all FPTC patients should be
treated with postoperative radioactive iodine abla-
tion, followed by thyroid hormone suppression. And
shorter distance between the nodule and capsule has
a greater risk of cervical lymph node metastasis,
which is consistent with previous report [18].
Moreover, given genetic predisposition for thyroid
cancer in these patients, any residual thyroid tissue is at
risk of developing into a malignancy. Therefore, a more
aggressive surgical strategy is recommended to obtain a
better relapse-free survival in this study.
Besides genetic factors, environmental hazards should
also be considered. Because it is elusive whether the in-
cidence of malignancy is caused solely by genetic inherit-
ance or by a combination of genetic predisposition and
environmental influence, such as exposure to a low
dosage of radiation, should not preclude the diagnosis of
this disease [19,20].
However, sufficient detailed interrogation and long-
term follow-up of the patients and their family arerequired to offer individualized recommendations ac-
cording to the risk of PCT in each subject.Conclusions
FPTC is more likely to possess aggressive features than
sporadic counterparts. Thus, screening of at-risk families
is essential to aid in earlier recognition. An aggressive
surgical strategy appeared to be the more effective therapy.
However, sufficient detailed interrogation and long-term
follow-up of the patients and their family are necessary for
providing individualized recommendations for clinical
management.
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